Virus-Like Particle Vaccination Protects Nonhuman Primates from Lethal Aerosol Exposure with Marburgvirus (VLP Vaccination Protects Macaques against Aerosol Challenges)
Open Access
Abstract
Marburg virus (MARV) was the first filovirus to be identified following an outbreak of viral hemorrhagic fever disease in Marburg, Germany in 1967. Due to several factors inherent to filoviruses, they are considered a potential bioweapon that could be disseminated via an aerosol route. Previous studies demonstrated that MARV virus-like particles (VLPs) containing the glycoprotein (GP), matrix protein VP40 and nucleoprotein (NP) generated using a baculovirus/insect cell expression system could protect macaques from subcutaneous (SQ) challenge with multiple species of marburgviruses. In the current study, the protective efficacy of the MARV VLPs in conjunction with two different adjuvants: QS-21, a saponin derivative, and poly I:C against homologous aerosol challenge was assessed in cynomolgus macaques. Antibody responses against the GP antigen were equivalent in all groups receiving MARV VLPs irrespective of the adjuvant; adjuvant only-vaccinated macaques did not demonstrate appreciable antibody responses. All macaques were subsequently challenged with lethal doses of MARV via aerosol or SQ as a positive control. All MARV VLP-vaccinated macaques survived either aerosol or SQ challenge while animals administered adjuvant only exhibited clinical signs and lesions consistent with MARV disease and were euthanized after meeting the predetermined criteria. Therefore, MARV VLPs induce IgG antibodies recognizing MARV GP and VP40 and protect cynomolgus macaques from an otherwise lethal aerosol exposure with MARV.Keywords
This publication has 52 references indexed in Scilit:
- Evaluation of Perceived Threat Differences Posed by Filovirus VariantsBiosecurity and Bioterrorism: Biodefense Strategy, Practice, and Science, 2011
- Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviationsArchives of Virology, 2010
- Prospects for immunisation against Marburg and Ebola virusesReviews in Medical Virology, 2010
- Vector Choice Determines Immunogenicity and Potency of Genetic Vaccines against Angola Marburg Virus in Nonhuman PrimatesJournal of Virology, 2010
- Protection of Nonhuman Primates against Two Species of Ebola Virus Infection with a Single Complex Adenovirus VectorClinical and Vaccine Immunology, 2010
- Single-Injection Vaccine Protects Nonhuman Primates against Infection with Marburg Virus and Three Species of Ebola VirusJournal of Virology, 2009
- Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvantJournal of Experimental Medicine, 2009
- Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg virusesVaccine, 2008
- Structure of the Ebola virus glycoprotein bound to an antibody from a human survivorNature, 2008
- Marburgvirus Genomics and Association with a Large Hemorrhagic Fever Outbreak in AngolaJournal of Virology, 2006